Gilead/Teva HIV Drug Patent Settlement Wasn’t Reverse Payment, Jury Finds
SAN FRANCISCO — A California federal jury has found that third-party payers and health insurers did not prove that an HIV patent settlement between Gilead Sciences Inc. and Teva Pharmaceuticals USA...To view the full article, register now.
Already a subscriber? Click here to view full article